2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2758 Treatment initiation and outcomes of older adults with Philadelphia-chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) in the United States

Cristian Camilo Taborda, MD, Rong Wang, PhD2, Lourdes Mendez, MD, Ph D3, Rory Shallis I, MD4, Xiaomei Ma, MD, PhD5, Nikolai Podoltsev, MD, PhD6
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Public Health, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Yale School of Public Health, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States

Introduction: Older adults with B-ALL historically had poor survival. Treatment options have expanded since 2015 with the introduction of novel immunotherapies, but population-level data on treatment initiation and outcomes remain limited. We leveraged data from the Surveillance, Epidemiology, and End Results (SEER) program and SEER-Medicare to evaluate survival trends, treatment initiation, and factors associated with timely treatment (TT, treatment within 90 days of diagnosis).

Methods: We assembled two cohorts of patients (pts) who were diagnosed with B-ALL (International Classification of Diseases for Oncology, 3rd Edition, histology codes 9811 and 9813–9819) during 2010-2021, with follow-up through December 31, 2022. The SEER cohort included pts aged ≥65 years and was used to compare overall survival (OS) across diagnosis eras (2010-2014 vs 2015-2021) and by age. The SEER-Medicare cohort included pts aged ≥66 years with continuous Medicare Parts A/B coverage and no health maintenance organization enrollment from 12 months before diagnosis through the end of follow-up. We evaluated systemic therapy receipt at any time and TT, early mortality, and hospice utilization. Frailty was assessed using an established claims-based algorithm. Multivariable logistic regression was performed to identify factors associated with TT. OS was estimated using Kaplan-Meier methods and compared using log-rank test. Multivariable Cox proportional hazards models were used to evaluate the associations of TT and diagnosis era with OS.

Results: The SEER cohort included 2,301 pts with a median age of 73 years; 52% were female, 62.9% were non-Hispanic White, and 24.1% were Hispanic. Median OS increased from 7 months (95% confidence interval [CI]: 6-8) in 2010-2014 to 11 months (95% CI: 10-13) in 2015-2021 (P<0.01). Median OS increased from 12 to 18 months among pts aged 65-74 years (P<0.01) and from 3 to 5 months among those aged ≥75 years (P=0.02).

The SEER-Medicare cohort included 1,274 pts with a median age of 75; 52.1% female and 80.9% non-Hispanic White. Overall, 831 (65.3%) received systemic therapy at any time, including 783 (61.5% of the cohort; 94.2% of treated pts) who received TT. Among pts receiving TT, median time from diagnosis to treatment was 23 days (interquartile range: 13-32). The proportion of pts receiving TT was stable over time (63.5% in 2010 vs 59.8% in 2021; P=0.74), and diagnosis era was not associated with TT (adjusted odds ratio [OR] for 2015-2021 vs 2010-2014 = 1.23, 95% CI: 0.94-1.62; P=0.14).

Advanced age, frailty, and residence in the South or non-metropolitan areas were independently associated with lower odds of TT. Compared with pts aged 66-69 years, those aged 75-79 years (OR=0.32, 95% CI: 0.21-0.49; P<0.01) and ≥80 years (OR=0.11; 95% CI 0.08-0.17, P<0.01) were less likely to receive TT. Frailty (OR=0.49, 95% CI: 0.35-0.68; P<0.01), residence in the South vs Northeast (OR=0.63, 95% CI: 0.42-0.94; P=0.02), and residence in non-metropolitan vs metropolitan areas (OR=0.57, 95% CI: 0.37-0.88; P=0.01) were also associated with lower odds of TT. The age-by-frailty interaction was not significant (P=0.34).

Pts receiving TT had longer median OS than those who did not (12.5 vs 2.2 months; P<0.01). Pts diagnosed in 2015-2021 had longer OS than those diagnosed in 2010-2014 (15.0 vs 9.2 months; P<0.01). In multivariable analysis, TT (hazard ratio [HR] = 0.60, 95% CI: 0.52–0.69, P<0.01) and diagnosis in 2015-2021 vs 2010-2014 (HR=0.82, 95% CI: 0.72–0.93, P=0.03) were associated with lower mortality. Among pts receiving TT, 90-day mortality after treatment initiation decreased from 25.2% in 2010-2014 to 17.2% in 2015-2021 (P<0.01). Overall, 43.9% enrolled in hospice, including 20.8% within 90 days of diagnosis. Early hospice enrollment was more common among pts without TT than among those receiving TT (41.8% vs 7.7%; P<0.01).

Conclusions: Survival among older pts with B-ALL improved over time, but the proportion receiving TT did not. Improved survival is likely due to better outcomes among treated pts, whereas unchanged TT limited the population-level impact of therapeutic advances. Fewer than half of the untreated pts entered hospice within 90 days of diagnosis, suggesting an opportunity to expand TT among selected older pts. Advanced age, frailty, and geographic disparities were independently associated with lower odds of TT, underscoring an urgent need to improve access to effective, frailty-adapted therapies.

Cristian Camilo Taborda, MD: No relevant conflicts of interest to declare.